Trending Stocks Today | Galmed Pharmaceuticals Soars 416.53%
September 17th - US stocks trending in regular trading hours.Gainers: $Galmed Pharmaceuticals(GLMD.US)$ shoots up 416.53% to $19.99 with a turnover of $1.08 billion. $BurgerFi International(BFI.US)$
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright analyst Mitchell Kapoor maintains $Summit Therapeutics(SMMT.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate
A 160% surge in a week, one good medicine is enough to change fate! What is summit therapeutics (SMMT.US)?
In the US stock market last week, a stock called Summit Therapeutics (SMMT.US) rose unexpectedly, not only surging 160% itself, but also lifting biotechnology companies such as BioNTech and Instil Bio along with it.
Summit Therapeutics Reports High Response Rates From Ivonescimab Trials in Cancer Studies
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Insider Buying: Summit Therapeutics Co-CEO & Executive Chairman Bought US$75m Of Shares
Robert Duggan Buys Handful Of Shares In Summit Therapeutics
Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Summit Therapeutics Analyst Ratings
Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous...
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $45
H.C. Wainwright analyst Mitchell Kapoor maintains $Summit Therapeutics(SMMT.US)$ with a buy rating, and adjusts the target price from $30 to $45.According to TipRanks data, the analyst has a success
Express News | Summit Therapeutics PLC : H.c. Wainwright Raises Target Price to $45 From $30
The increase within the year reached 1123%! The cooperation between Chinese and American pharmaceutical companies defeated the "global pharmaceutical king", and the CEO said straightforwardly, "We are on the right side".
Summit Pharmaceuticals has surpassed the global drug king pembrolizumab from China's pharmaceutical company Akeso with its new drug Yervoy (PD-1/VEGF bispecific antibody) in a head-to-head clinical trial.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Is Summit Therapeutics Inc. (NASDAQ:SMMT) an Unstoppable Growth Stock To Buy Now?
Trending Stocks This Week as Market Bounces Back From Selloff
Summit Boosts Instil, BioNTech as Lead Drug Beats Merck's Keytruda
Summit Therapeutics Shares Are Trading Higher After the Company on Thursday Announced It Raised $235 Million in Net Proceeds.